|
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D) Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D) conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D) Clinical research trials and Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D) health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D). Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D) Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D) clinical trial. Subjects frequently get the best healthcare possible for their Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D) condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)  Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)
For Condition: Coronary Disease,Diabetes Mellitus,Insulin Resistance,Heart Diseases,Cardiovascular Diseases,Diabetes Mellitus, non-insulin dependent
Status: Recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) , National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Synopsis: The BARI 2D trial is a multicenter study that uses a 2x2 factorial design, with 2800 patients being assigned at random to initial elective revascularization with aggressive medical therapy or aggressive medical therapy alone with equal probability, and simultaneously being assigned at random to an insulin providing or insulin sensitizing strategy of glycemic control (with a target value for HbA1c of <7.0% for all patients). SPECIFIC AIMS A. Primary Aim The primary aim of the BARI 2D trial is to test the following two hypotheses of treatment efficacy in 2800 patients with Type 2 diabetes mellitus and documented stable CAD, in the setting of uniform glycemic control and intensive management of all other risk factors including dyslipidemia, hypertension, smoking, and obesity: 1. Coronary Revascularization Hypothesis: a strategy of initial elective revascularization of choice (surgical or catheter-based) combined with aggressive medical therapy results in lower 5-year mortality compared to a strategy of aggressive medical therapy alone; 2. Method of Glycemic Control Hypothesis: with a target HbA1c level of <7.0%, a strategy of hyperglycemia management directed at insulin sensitization results in lower 5-year mortality compared to a strategy of insulin provision. B. Secondary Aims The secondary aims of the BARI 2D trial include: a) comparing the death, myocardial infarction or stroke combined endpoint event rate between the revascularization versus medical therapy groups and between the insulin sensitization versus insulin provision groups; b) comparing rates of myocardial infarction, other ischemic events, angina and quality of life associated with each revascularization and hyperglycemia management strategy; c) evaluating the relative economic costs associated with the trial treatment strategies, d) exploring the effect of glycemic control strategy on the progression and mechanism of vasculopathy including changes in PAI-1 gene expression.
Details: BACKGROUND: Type 2 diabetes mellitus, which is becoming more prevalent in our society as the population ages, is one of the strongest risk factors for coronary artery disease (CAD) and consequent mortality. In addition to generating an enormous toll in human suffering, diabetes places an economic burden approaching 100 billion dollars annually on the U.S. health care system. Despite the well known dismal prognosis of diabetes complicated by angiographically documented CAD, the optimal treatment paradigm for this large group of patients has not been studied. Coronary revascularization, while increasingly used, has not been directly shown to be of additional benefit to simultaneous intensive medical management of CAD along with management of hyperglycemia, hypertension, dyslipidemia, and other risk factors. Moreover, while intensive efforts to lower HbA1c have been demonstrated to favorably affect the clinical course of Type 2 diabetes mellitus in terms of microvascular complications, the optimal hyperglycemia management strategy with regard to macrovascular outcome is not known. These critical treatment dilemmas have motivated the development of BARI 2D, a multicenter randomized trial designed to determine in patients with Type 2 diabetes and stable CAD: 1) the efficacy of initial elective coronary revascularization combined with aggressive medical therapy, compared to an initial strategy of aggressive medical therapy alone; and 2) the efficacy of a strategy of providing more insulin (endogenous or exogenous), versus a strategy of increasing sensitivity to insulin (reducing insulin resistance), in the management of hyperglycemia, with a target HbA1c level of < 7.0% for each strategy. DESIGN NARRATIVE: The BARI 2D trial is a multicenter study that will use a 2x2 factorial design, with 2800 patients being assigned at random to initial elective revascularization with aggressive medical therapy or aggressive medical therapy alone with equal probability, and simultaneously being assigned at random to an insulin providing or insulin sensitizing strategy of glycemic control (with a target value for HbA1c of <7.0% for all patients). Following confirmation of patient eligibility and provision of written consent, patients will be randomized as shown below: Number of Patients Per Treatment Assignment Revascularization Strategy Revascularization Medical Glycemic Control Strategy Insulin Providing (IP) 700 700 Insulin Sensitizing (IS) 700 700
Eligibility:
Study Type: Interventional, Treatment, Randomized, Factorial Assignment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria for BARI 2D 1. Diagnosis of Type 2 diabetes mellitus. 2. Coronary arteriogram showing one or more vessels amenable to revascularization (=50% stenosis). 3. Objective documentation of ischemia OR subjectively documented typical angina with =70% stenosis in at least one artery. 4. Suitability for coronary revascularization by at least one of the available methods (does not require the ability to achieve complete revascularization). 5. Ability to perform all tasks related to glycemic control and risk factor management. 6. Age 25 or older. 7. Informed written consent. Exclusion Criteria for BARI 2D 1. Definite need for invasive intervention as determined by the attending cardiologist. 2. Prior bypass surgery (CABG) or prior catheter-based intervention within the past 12 months. 3. Planned intervention for disease in bypass graft(s) if the patient is randomized to a strategy of initial revascularization. 4. Class III or IV CHF. 5. Creatinine > 2.0 mg/dl. 6. HbA1c > 13%. 7. Need for major vascular surgery concomitant with revascularization (e.g., carotid endarterectomy). 8. Left main stenosis > 50%. 9. Non-cardiac illness expected to limit survival. 10. Hepatic disease (ALT> 2 times the ULN). 11. Fasting triglycerides > 1000 mg/dl in the presence of moderate glycemic control (HbA1c <9.0%). 12. Current alcohol abuse. 13. Chronic steroid use judged to interfere with the control of diabetes, exceeding 10 mg. of Prednisone per day or the equivalent. 14. Pregnancy, known, suspected, or planned in next 5 years. 15. Geographically inaccessible or unable to return for follow-up. 16. Enrolled in a competing randomized trial or clinical study. 17. Unable to understand or cooperate with protocol requirements. Patients with Type 2 diabetes mellitus and CAD documented by coronary arteriography will be eligible for the trial if revascularization is not required for prompt control of severe or unstable angina. Diabetic patients who are being treated with insulin or oral hypoglycemic drugs will be eligible as well as diabetic patients treated with diet and exercise alone provided that a diagnosis of diabetes can be confirmed by record review or that a fasting plasma glucose (FPG)>125/mg/dl (7.0 mmol/l) can be obtained. The determination of suitability for BARI 2D will be made by a physician-investigator at each participating institution on clinical grounds at the time of coronary angiography. Significant CAD will be defined as at least one stenosis >50%. Angina and ischemia will be assessed by use of patient self-report, physician examination, and appropriate diagnostic measures including exercise myocardial perfusion imaging, exercise echocardiography, and IV dipyridamole or adenosine myocardial perfusion imaging or invasively by doppler or pressure wire. Objective documentation of myocardial ischemia includes any of the following: 1. Exercise or pharmacologically-induced: a. =1 mm of horizontal or downsloping ST depression or elevation for =60-80 milliseconds after the end of the QRS complex; b. myocardial perfusion defect; c. myocardial wall motion abnormality. 2. Stabilized, prior acute coronary syndrome with CK-MB or troponin elevation or with new, =0.5 mm ST depression or elevation, or T wave inversion of =3 mm in 2 contiguous ECG leads. 3. Doppler or pressure wire showing coronary flow reserve (CFR) <2.0 or fractional flow reserve (FFR) <0.75. Among patients without documented ischemia, only patients with stenosis = 70% presenting with classic anginal symptoms will be eligible for randomization.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BernardChaitman, , St. Louis University
University of Pittsburgh *Recruiting*
Pittsburgh, Pennsylvania, 15213
United States
Recruiting Glory Koerbel 412-383-8703
Fletcher Allen Health Care *Recruiting*
Burlington, Vermont, 05401
United States
Recruiting Michaelanne Rowen 802-847-4746
University of Ottawa Heart Institute *Recruiting*
Ottawa, Ontario, K1Y 4W7
Canada
Recruiting Melody Dallaire (613) 761-5208
Ohio State University Medical Center *Recruiting*
Columbus, Ohio, 43210
United States
Recruiting Cecilia Boyer 614-292-3177
Boston Medical Center *Recruiting*
Boston, Massachusetts, 02118
United States
Recruiting Deb Gannon 617-638-8751
University of Maryland Hospital *Recruiting*
Baltimore, Maryland, 21201
United States
Recruiting Thomas Donner 410-328-6542
New York University School of Medicine *Recruiting*
New York City, New York, 10016
United States
Recruiting Susan Cotton 212-263-7224
Saint Joseph Mercy Hospital *Recruiting*
Ann Arbor, Michigan, 48106
United States
Recruiting Penny Wilms 734-712-5675
Baylor College of Medicine *Recruiting*
Houston, Texas, 77030
United States
Recruiting Bella Belleza-Bascon 713-394-6917
New York Medical College/Westchester Medical Center *Recruiting*
Valhalla, New York, 10595
United States
Recruiting Jane Rainaldi 914-493-8815
Mid America Heart Institute *Recruiting*
Kansas City, Missouri, 64111
United States
Recruiting Aimee Long 816-932-5719
University of Virginia *Recruiting*
Charlottesville, Virginia, 22908
United States
Recruiting Karen Murie 434-982-1058
Montreal Heart Institute *Recruiting*
Montreal, Quebec,
Canada
Recruiting Johanne Trudel (514) 376-3330
University of Minnesota *Recruiting*
Minneapolis, Minnesota, 55455
United States
Recruiting Julie Dicken 612-625-9477
Quebec Heart Institute/Laval Hospital *Recruiting*
Sainte-Foy, Quebec, G1V 4G5
Canada
Recruiting Giles Dagenais (418) 656-8711
Henry Ford Hospital Systems *Recruiting*
Detroit, Michigan, 48202
United States
Recruiting Raquel Pangilinan 313-916-4268
University of Alabama at Birmingham *Recruiting*
Birmingham, Alabama, 35294
United States
Recruiting Roberta Hill 205-934-7661
Saint Louis University Health Sciences Center *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting Sharon Plummer 314-977-7536
Lahey Clinic Medical Center *Recruiting*
Burlington, Massachusetts, 01805
United States
Recruiting Lisa Abel 781-744-8885
University of Maryland Hospital *Recruiting*
Baltimore, Maryland, 21201
United States
Recruiting Warren Laskey 410-328-2058
Saint Lukes-Roosevelt Hospital Center *Recruiting*
New York City, New York, 10025
United States
Recruiting Jeanine Albu 212-523-4183
Northwestern University *Recruiting*
Chicago, Illinois, 60611
United States
Recruiting Lorene Eckman 312-926-5421
University of Texas Health Science Center, San Antonio *Recruiting*
San Antonio, Texas, 78251
United States
Recruiting Robin Prescott 210-617-5300
Additional Information:
Study ID Numbers: 133;
Study Start Date: September 2000
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006305
Other Heart Diseases Studies:
1. Women's Healthy Lifestyle Project: Cardiovascular Risk Factors and Menopause
2. Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients
3. Soy Protein in Early Diabetic Nephropathy
4. Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus
5. Incidence of Diabetes and Cardiovascular Disease in Mexican Americans
Related Studies:
Other Heart Diseases Clinical Trials
Other Minnesota Clinical Trials
Other Minneapolis Clinical Trials
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)
|
|
|
|
|
|
|
|
